Similar articles

• Drug discovery process for kinase inhibitors.

  Weinmann H, Metternich R. Weinmann H, et al. Chembiochem. 2005 Mar;6(3):455-9. doi: 10.1002/cbic.200500034. Chembiochem. 2005. PMID: 15742380 No abstract available.
• Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.

  Vieth M, Erickson J, Wang J, Webster Y, Mader M, Higgs R, Watson I. Vieth M, et al. J Med Chem. 2009 Oct 22;52(20):6456-66. doi: 10.1021/jm901147e. J Med Chem. 2009. PMID: 19791746
• Small-molecule kinase-inhibitor target assessment.

  Kung C, Shokat KM. Kung C, et al. Chembiochem. 2005 Mar;6(3):523-6. doi: 10.1002/cbic.200400393. Chembiochem. 2005. PMID: 15696508
• Doing more than just the structure-structural genomics in kinase drug discovery.

  Marsden BD, Knapp S. Marsden BD, et al. Curr Opin Chem Biol. 2008 Feb;12(1):40-5. doi: 10.1016/j.cbpa.2008.01.042. Epub 2008 Feb 29. Curr Opin Chem Biol. 2008. PMID: 18267130 Review.
• Insights for the development of specific kinase inhibitors by targeted structural genomics.

  Fedorov O, Sundström M, Marsden B, Knapp S. Fedorov O, et al. Drug Discov Today. 2007 May;12(9-10):365-72. doi: 10.1016/j.drudis.2007.03.006. Epub 2007 Mar 29. Drug Discov Today. 2007. PMID: 17467572 Review.